Preclinical assays of EM1 calcitriol analogue alone and in combination with paclitaxel.

FERRONATO MJ; COLÓ GP; GUEVARA JA; NADAL SERRANO M; ARRIBAS J; BERNARDO MORALES C; VITALE C; IBARRA A; FACCHINETTI MM; CURINO AC

Bariloche

Simposio; The Fourth South American Symposium in Signal Transduction and Molecular Medicine (SISTAM); 2018

Triple Negative Breast Cancer (TNBC) lacks the molecular targets commonly used to treat hormone receptor- and HER2- expressing BC and, thus, mortality and morbidity remains high. Therefore, novel candidate molecular targets or drugs are needed to treat this subtype of tumors. We have previously reported that the vitamin D analogue EM1 elicited strong antitumor effects, specifically by targeting the metastatic process, in the LM3 hormone-independent BC cell line and animal model. Hence, the aim of the present study was to continue the preclinical assays by evaluating the antineoplastic effects of EM1 alone or in combination with paclitaxel in TNBC- cell lines and patient-derived xenografts (PDXs). The results show that EM1 decreases the viability of the TNBC cell line 4T1 (p